Superluminal Medicines, Inc., a Boston-based biotechnology firm, has successfully raised $5 million through a debt offering, as reported in their recent SEC Form D filing. The fundraising effort, which took place on August 14, 2025, is fully subscribed to the total offering amount.
Related articles
Press ReleaseMay 25, 2026
FinVolution Group Announces New Share Repurchase Program of Up to US$150 million
May 25, 2026
Press ReleaseMay 25, 2026
TECO Signs Acquisition Agreement with Malaysia's Dynaciate, Targeting Exponential AIDC Revenue Growth Next Year
May 25, 2026
Press ReleaseMay 25, 2026
Cyient Semiconductors Announces Strategic Financing with Edelweiss at ~ USD 500 Mn. Equity Valuation
May 25, 2026
← Back to all articles
Generated by Olivia 6